What is ENDRA Life Sciences?
ENDRA Life Sciences, founded in 2009 and headquartered in Ann Arbor, Michigan, is dedicated to the early detection of liver disease. The company's innovative approach aims to provide critical diagnostic tools, addressing a significant unmet need in healthcare. This strategic financing positions ENDRA Life Sciences to further its development and market penetration in the competitive medical technology sector.
How much funding has ENDRA Life Sciences raised?
ENDRA Life Sciences has raised a total of $27.9M across 4 funding rounds:
Stock Offering
$8.4M
Debt
$150K
Private Equity
$4.9M
Private Equity
$14.4M
Stock Issuance/Offering (2017): $8.4M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Private Equity (2025): $4.9M, investors not publicly disclosed
Private Equity (2025): $14.4M, investors not publicly disclosed
What's next for ENDRA Life Sciences?
The recent major strategic investment signals a new phase of growth and development for ENDRA Life Sciences. This capital infusion is expected to accelerate the company's research and development initiatives, potentially leading to expanded clinical trials and broader market adoption of its diagnostic technologies. The company's focus on early disease detection aligns with growing healthcare trends emphasizing preventative medicine and improved patient outcomes.
See full ENDRA Life Sciences company page
